Tersolisib

DB21752InvestigationalSmall molecule

STX-478 is under investigation in clinical trail NCT05768139 (First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors).

Mechanism: Pharmacologically active on Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform
Curator reviewed
Formula / weight: C₁₆H₁₂F₅N₅O₂ · 401.297 g/mol (avg)
Code names: AGX9NKC8M9 · LY4064809 · STX-478

Resolves to

Compound

UNIIAGX9NKC8M9CAS2883540-92-7ChEMBLCHEMBL5421037ChEBI759837PubChem166532451

Structure

InChIKeyLGPNQALKGDDVBD-CYBMUJFWSA-NSMILESCC1=C(OC2=C1C=C(F)C=C2F)[C@@H](NC(=O)NC1=CN=C(N)N=C1)C(F)(F)F

Targets

P42336PIK3CA

What you can answer from here — as of September 23, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

6Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Tersolisib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account